biopharmaceutical company
2910 Seventh Street Berkeley CA 94710, Berkeley, CA · PAT SCANNON
| Year | Client | Period | Income | Expenses | Doc |
|---|---|---|---|---|---|
| 2009 | XOMA CORPORATION (FKA XOMA (US) LLC) |
3rd Quarter (July 1 - Sep 30) AMENDED |
— | $100,000 | |
| 2009 | XOMA CORPORATION (FKA XOMA (US) LLC) |
1st Quarter (Jan 1 - Mar 31) AMENDED |
— | $140,000 | |
| 2009 | XOMA CORPORATION (FKA XOMA (US) LLC) |
4th Quarter (Oct 1 - Dec 31) 4th Quarter - Report |
— | $50,000 | |
| 2009 | XOMA CORPORATION (FKA XOMA (US) LLC) |
3rd Quarter (July 1 - Sep 30) 3rd Quarter - Report |
— | $90,000 | |
| 2009 | XOMA CORPORATION (FKA XOMA (US) LLC) |
2nd Quarter (Apr 1 - June 30) 2nd Quarter - Report |
— | $120,000 | |
| 2009 | XOMA CORPORATION (FKA XOMA (US) LLC) |
1st Quarter (Jan 1 - Mar 31) 1st Quarter - Report |
— | $130,000 |
| Client | Filings | Total Income |
|---|---|---|
| XOMA CORPORATION (FKA XOMA (US) LLC) | 29 | — |
| Name | Disclosed Prior Position |
|---|---|
| DAN CAFARO | Vice President, Regulatory Affairs and Compliance |
| STEVEN B ENGLE | President CEO |
| BETH RADA | |
| PATRICK JEROME SCANNON | Executive Vice President and Chief Biotechnology Officer |
| ROBERT TENEROWICZ | Vice President, Operations and Biodefense Business |